AvePoint launches AI data classification & recovery

AvePoint launched Kinetic Classification and added features to Rapid Recovery to improve AI-era data governance and incident recovery. Kinetic continuously re-evaluates data sensitivity across Microsoft 365, Google Workspace and apps like GitHub and AWS S3. Rapid Recovery adds restore-priority recommendations, a recovery-plan wizard, and Express Recovery for Entra ID. AvePoint cites its State of AI Report survey results.

Original reporting
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 4:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AvePoint launches AI data classification & recovery — source image
Decision brief

The 30-second read

Low
01

Why it matters

The new tools target a practical enterprise pain point: keeping data classification current as permissions, ownership, and usage evolve, and using that context to decide what to restore first during cyber events.

02

Market read

This is a vendor product launch aimed at AI data governance and incident recovery workflows, but it does not provide financial metrics or adoption data that would likely drive a tradable repricing.

03

What to watch

Traders may be over-weighting the AI governance theme; without adoption metrics or competitive displacement details, the market reaction may be muted.

Relevance 5/10Novelty 5/10Timing: product launch reported today (2026-08-05)

Background

AvePoint introduced Kinetic Classification and expanded Rapid Recovery to support continuous data sensitivity reassessment and prioritized restoration after incidents.

Market effects

Highlights growing enterprise demand for AI data governance and faster, data-aware recovery planning across cloud collaboration and identity systems.

No specific regional demand or regulatory trigger mentioned.

Positioned as a cross-cloud capability (Microsoft 365, Google Workspace, AWS S3) relevant to multinational deployments.

Counterpoint

The article is a feature launch narrative without disclosed customer wins, pricing, or measurable performance benchmarks, limiting near-term earnings impact visibility.

Key entities

  • AvePoint

    Launched Kinetic Classification and added recovery features to Rapid Recovery for AI-era data governance and restoration.

  • Kinetic Classification

    Continuously reassesses data sensitivity and retention signals across multiple cloud applications instead of one-off labels.

  • Rapid Recovery

    Added priority-data recommendations, a recovery-planning wizard, and Express Recovery for Entra ID to incorporate identity into recovery.

Related articles

$AVPTMedAI 9/10

AvePoint (AVPT) Q2 2026 Earnings Call Transcript

AvePoint (AVPT) reported Q2 2026 revenue of $124.5M, up 22% YoY, with SaaS revenue $98.5M (79% of total). Total ARR was $465.1M (+27%), net new ARR $29.9M, and GAAP operating margin 8.2%. Full-year guidance: ARR $522.1M-$528.1M and revenue $508.5M-$512.5M. The company also spent $50M on share repurchases in Q2.

$AVPTHighAI 9/10

AvePoint lifts annual recurring revenue guidance after Q2

AvePoint reported Q2 2026 revenue of $124.5M and raised full-year annual recurring revenue guidance. SaaS revenue was $98.5M, up 27% y/y, and ARR ended at $465.1M, up 27%. Q3 revenue is forecast at $128.2M to $130.2M, and full-year ARR at $522.1M to $528.1M. The company cited demand for AI governance.

$AVPTHigh

AvePoint, Inc. (AVPT): Results of Operations and Financial Condition

AvePoint, Inc. (AVPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 AvePoint Announces Second Quarter 2026 Financial Results Second quarter SaaS revenue of $98.5 million, representing 27% year-over-year growth, 26% on a constant currency basis Second quarter Total revenue of $124.5 million, representing 22% year-over-year growth, 21%

$TENXMedAI 8/10

Tenax Therapeutics Presents Additional Phase 3 LEVEL Data Showing TNX-103 Benefits in PH-HFpEF Patients With Lower Baseline Walk Distance

Tenax Therapeutics (TENX) presented additional Phase 3 LEVEL trial data showing TNX-103 improved 6MWD, NT-proBNP, and RVSP in PH-HFpEF patients with lower baseline walk distance. The company plans to enrich the LEVEL-2 population based on these results. TNX-103 showed a 26.3m 6MWD improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction vs. placebo in this subgroup.

$MRKMedAI 8/10

Jarvis: A cancer vaccine is closer than ever

Merck & Co. and Moderna Inc. reported positive late-stage trial results for their mRNA cancer vaccine, intismeran, combined with Keytruda, showing extended time before melanoma recurrence. Moderna's stock more than doubled. Full data pending.

$TENXMedAI 8/10

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Tenax Therapeutics presented Phase 3 LEVEL trial results at ESC Congress 2026. TNX-103 showed significant improvements in patients with PH-HFpEF and baseline 6MWD below 333 meters, including a 26.3m walk distance improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction. The company plans to enrich the population for the next study.